FDA Accepts Biohaven's Resubmitted Ataxia Drug For Review, Sets First-Quarter 2027 Goal Date
The agency will also convene an advisory committee on troriluzole, a second step before any approval decision, Biohaven said.
The FDA has accepted for review Biohaven's resubmitted new drug application for Vyglxia (troriluzole) in spinocerebellar ataxia and set a goal date in the first quarter of 2027, according to an 8-K the company filed Thursday. The agency also plans to convene an outside advisory committee before it decides.
What the 8-K says
Biohaven told the SEC that the FDA considers the resubmission a complete response to its November 4, 2025 action letter. That classification matters because it sets the review clock: the agency assigned a user fee goal date in the first quarter of 2027.
The resubmission included new positive supportive analyses, the company said. The filing does not detail them.
The FDA plans to hold a meeting of its Peripheral and Central Nervous System Advisory Committee to get input from external stakeholders. The filing says the anticipated meeting date will be forthcoming in the near term.
What it changes
Acceptance means the drug is back under active FDA review. An advisory committee adds a public step between the resubmission and a decision.
The filing's cautionary note is blunt that the goal date is not a promise. It says the target date is a goal and does not assure that the FDA will act by then or approve the application. The agency may extend the review, including if it judges that information submitted during the review is a major amendment, may ask for more information, or may issue a complete response letter.
The filing also states that troriluzole is an investigational drug and has not been approved for any indication in the United States.
The update was furnished under Regulation FD, the rule on disclosing information to all investors at once. Matthew Buten, the chief financial officer, signed it.
What to watch
The date of the advisory committee meeting, which Biohaven says is coming soon, and then the FDA's decision against the first-quarter 2027 goal date.
The next datable item is the advisory committee meeting date, which the filing promises in the near term.
Sources
- 8-K Filing — Biohaven Ltd. (BHVN) — SEC EDGAR
